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PURPOSE. To describe the incidence rate of age-related macular
degeneration (AMD) and the progression rates of early stages
of age-related maculopathy (ARM), and to study the hierarchy
of fundus features that determine progression.
METHODS. A group of 4953 subjects aged 55 years and older
living in Rotterdam, The Netherlands, was studied at baseline
and at 2-year follow-up to determine the incidence of neovas-
cular and atrophic AMD. A subgroup of 1244 subjects was
studied for progression of early stages of ARM. Fundus trans-
parencies were graded for features of ARM using the Interna-
tional Classification System. ARM was stratified in four exclu-
sive stages, according to type of drusen and presence of
pigmentary irregularities.
RESULTS. The overall 2-year cumulative incidence of AMD was
0.2%, increasing to 1.8% in subjects of 85 years and older. Of
those in the early stages, one fourth showed progression to a
more severe stage. The most important predictors for progres-
sion were more than 10% of macular area covered by drusen
(odds ratio [OR] 5.7, 95% confidence interval [CI] 2.9–11.3),
presence of depigmentation (OR 4.0, 95% CI 2.5–6.4), and
hyperpigmentation (OR 3.4, 95% CI 2.1–5.4).
CONCLUSIONS. The incidence of AMD appears to be lower in The
Netherlands than in the United States. Progression of early
ARM stages occurs in a distinct pattern at a stable rate, with a
large area of drusen and presence of pigmentary changes as the
most important predictors. (Invest Ophthalmol Vis Sci. 2001;
42:2237–2241)
Many studies have contributed to the current knowledgethat age-related maculopathy (ARM) is a frequent eye
disorder in the elderly.1–3 Its end stages, referred to as age-
related macular degeneration (AMD), have been shown to be
the most important cause of irreversible blindness in the West-
ern world.4–6 The epidemiologic designs of the population-
based studies that provided these data have been mostly cross-
sectional, allowing for data on disease prevalence and
prevalence associations. In etiologic research, however, inci-
dence is preferred over prevalence, because this represents the
actual disease occurrence. Incidence data for ARM would im-
prove the knowledge on the origin, early development, and
progression of this disease. At present, these data are still
scarce.7,8
The purpose of this study was to describe the incidence and
progression rates of ARM in the population-based Rotterdam
Study in The Netherlands. We studied the incidence of AMD in
the entire cohort and investigated progression of early ARM
features in specific subgroups. Furthermore, we sought to
assess the prognostic value of the various fundus features that
are associated with ARM.
MATERIALS AND METHODS
Population
The Rotterdam Study is a population-based prospective cohort study
conducted in a suburb of Rotterdam, The Netherlands, in which
chronic ophthalmologic, neurologic, cardiovascular, and locomotor
disorders are investigated. Methods used to identify and describe the
population have appeared in previous reports.2,9 The study protocol
was approved by the medical ethics committee of Erasmus University,
and the research was in accordance with the tenets of the Declaration
of Helsinki. Written informed consent was obtained from all partici-
pants after explanation of the nature of the study. Baseline interviews
and screening examinations took place from 1990 to mid-1993 and
follow-up examinations from mid-1993 to the end of 1994.
Of 10,275 subjects aged 55 years and older living in Ommoord (a
suburb of Rotterdam), 7,983 (78%) agreed to participate in the baseline
phase of the entire study. The eye examination became part of the
Rotterdam Study after the initial phase, therefore a smaller portion (n
5 6872) was eligible for ophthalmic study. Gradable fundus transpar-
encies were available on 6418 (93%) subjects, in 105 (1.6%) of whom
atrophic or neovascular AMD was diagnosed. This resulted in a cohort
of 6313 subjects potentially at risk for incident AMD.
Procedures and Definitions
The screening for presence of ARM followed the same protocol at
baseline and at follow-up. The procedures have been described in
detail elsewhere.2,9 During the screening eye examination, 35° color
transparencies were taken of the macular area (model TRV-50VT fun-
dus camera; Topcon Optical Co., Tokyo, Japan). The diagnosis of ARM
features was based on grading of fundus transparencies according to
the International Classification System,10 in which all features of macu-
lopathy related to age are named ARM and its late stages (i.e., atrophic
or neovascular macular degeneration) are named AMD. At baseline,
fundus transparencies of the entire cohort were graded in a detailed
manner to identify all features of ARM in the macular grid area (radius,
3000 mm). At follow-up, all fundus transparencies of the entire cohort
were graded for presence of AMD using side-by-side grading with the
transparencies of the baseline phase. Inter- and intragrader agreement
on each fundus feature was regularly assessed, and consensus training
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was initiated when k values were below 0.6. All photographs showing
AMD and all uncertain diagnoses were adjudicated by senior investi-
gators (PTVMdeJ, CCWK, JRV).
To assess the incidence and progression rates of early ARM fea-
tures, ARM at baseline was stratified in four exclusive stages of disease
(Table 1). On the basis of previous findings,7,8,11,12 we assumed more
macular disease and a higher risk of development of AMD with each
successive stage of early ARM. Stratification was based on the eye with
the most severe stage. ARM stages 1a and 1b were considered one
stage of clinical severity, as were stages 2a and 2b. For reasons of
feasibility and efficiency, only a randomly selected subset of subjects
with no ARM or ARM stage 1a at baseline underwent detailed grading
of early ARM features at follow-up. For the remaining stages, the entire
group of subjects with gradable fundus transparencies underwent
detailed grading at follow-up. All detailed grading at follow-up was
performed using side-by-side grading with the transparencies from
baseline.
Incidence of an ARM lesion was defined as absence of this partic-
ular lesion within the grid area of either eye at baseline and presence
of this lesion in at least one eye at follow-up. Progression of ARM was
defined as a worsening to the next or a higher stage of ARM; no
progression was defined as no change or a decrease in stage.
Statistical Methods
Subjects with AMD at baseline were excluded from the incidence and
progression analyses. The age-specific incidence rates of AMD were
obtained per 10-year age categories by dividing the number of incident
cases by the number of person-years per age category. The latter was
calculated by summing each participant’s contribution of follow-up
time per age category. Confidence intervals of incidence rates were
calculated with the exact method. Age at onset of incident AMD was
set at the midpoint between age at baseline and age at follow-up.
Cumulative incidences were calculated from the incidence rates with
the formula
CIt 5 1 2 e
2IRpt
where CI is the cumulative incidence over a period of t years, IR is the
incidence rate, and e is the constant 2.71828, which is the base of the
natural logarithm. Incidence of AMD in the contralateral eye of subjects
with unilateral AMD at baseline was analyzed in a separate analysis.
Progression of early ARM stages was studied by logistic regression
analysis with age, gender, baseline stage of ARM and duration of the
follow-up period fixed in the model. In an initial analysis with these
fixed factors, the predictive powers of drusen size and location, pro-
portion of macular grid area covered by drusen, most frequent drusen
size, largest drusen size, drusen confluence, presence and area of
hyperpigmentation, and presence and area of depigmentation were
assessed. Statistical interaction between macular area of drusen and
hyper- or depigmentation, between hyper- and depigmentation, as well
as between area of drusen and drusen confluence, was studied by
entering the product term of these factors in the model. Determinants
or product terms with a significant odds ratio (OR) were entered in a
subsequent multivariate analysis to determine the independence and
magnitude of prognostic factors.
RESULTS
Incidence of AMD
Of the 6313 subjects at risk for incident AMD, 326 subjects
died before follow-up. Of the remaining 5987 subjects, 5445
(91%) responded to the 2-year follow-up phase of the Rotter-
dam Study, and 5095 (85%) participated in the rescreening eye
examination. Gradable fundus transparencies of at least one
eye were present in 4953 subjects (83%), and these subjects
were included in the incidence analyses. They significantly
differed from other eligible subjects in age, gender, smoking
status, and vascular status (Table 2). After adjustment for age,
those alive and nonparticipating at follow-up did not differ by
stage of ARM at baseline, nor were those who were deceased
at the time of follow-up different in ARM stage at baseline from
those participating (latter data not shown). Thus, there was no
significant selection of those included in the incidence analysis
on the basis of disease.
After an average follow-up period of 2.0 6 0.6 years (SD),
incident AMD was identified in 12 participants. Of those, four
had atrophic AMD and eight had neovascular AMD. Given a
total of 9849 person-years, the overall incidence rate of AMD
was 1.2 per 1000 person-years (2-year cumulative incidence
0.24%). The incidence rate increased with age (Table 3). Figure
1 shows the age-specific incidence rates in the Rotterdam
Study in comparison with two other population-based inci-
dence studies.7,8
TABLE 1. Stratification of ARM in Exclusive Stages of Severity
Stage Criteria
At
Baseline
At
Follow-
up
Selected
for
Detailed
Grading
No ARM No ARM features or only
drusen #63 mm
4038 3238 365
1a Soft, distinct drusen 1485 1160 348
1b Pigmentary irregularities 307 217 193
2a Soft, indistinct, or reticular
drusen
191 133 133
2b Soft, distinct drusen with
pigmentary irregularities
209 158 158
3 Soft, indistinct, or reticular
drusen with pigmentary
irregularities
83 47 47
4 Atrophic or neovascular
macular degeneration
(AMD)
105 56 0
Data are the number of subjects at each stage.
TABLE 2. Baseline Characteristics of Subjects at Risk of Incident ARM
In
Analysis*
(n 5 4953)
Not in
Analysis†
(n 5 1034) P‡
Age at baseline ,0.001
55–64 y 43.3 28.5
65–74 y 38.1 32.9
75–84 y 16.2 29.7
851 y 2.5 8.9
Gender (women) 58.5 61.3 0.07
Institutionalized 3.0 10.3 ,0.001
ARM stage at baseline 0.24
1 27.8 29.3
2 5.9 7.5
3 0.9 2.4
Smoking 0.01
Currently 20.4 23.1
Formerly 42.3 35.5
Hypertension 27.7 35.6 0.02
Atherosclerosis 14.2 24.7 ,0.001
Data are percentages of eligible subjects alive at the 2-year follow-
up. Total alive was 5987.
* Subjects with gradable fundus transparencies.
† Nonparticipants alive at follow-up, and subjects with ungradable
fundus transparencies.
‡ Adjusted for age and gender, when appropriate.
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Overall, there were no statistically significant gender differ-
ences in incidence rates of AMD. Among the 2080 men, the
overall incidence rate was 1.00 per 1000 person-years (2-year
cumulative incidence 0.2%), whereas among the 2873 women,
the overall incidence rate was 1.37 per 1000 person-years
(2-year incidence 0.2%, P 5 0.99, adjusted for age and fol-
low-up time).
Incident AMD was strongly associated with stage of ARM at
baseline. Neither ARM stage 0 nor stage 1 progressed to inci-
dent AMD. ARM stage 2 progressed in two subjects to incident
atrophic AMD and in five to incident neovascular AMD. For this
stage, the overall incidence rate of AMD was 14.0 per 1000
person-years (2-year cumulative incidence 3%), ranging from 0
per 1000 person years in subjects under 65 years to 25.7 per
1000 person-years (2-year incidence 5.0%) in subjects aged 85
years and older. Stage 3 at baseline progressed in two subjects
to incident atrophic AMD and in three to incident neovascular
AMD. For stage 3, the total incidence rate of AMD was 48.2 per
1000 person-years (2-year incidence 9%), and the age category
in which this occurred was less than 85 years.
Of the 31 subjects with AMD in only one eye at baseline,
incident AMD had developed in the second eye in three sub-
jects with atrophic AMD and in three subjects with neovascular
AMD, by the 2-year follow-up. This resulted in an incidence
rate of 170.6 per 1000 person-years (2-year cumulative inci-
dence 28.9%) for involvement of the second eye. In the three
subjects with unilateral atrophic AMD at baseline, the same
type of AMD developed in the second eye. Neovascular AMD
developed in the second eye of two of the three subjects with
neovascular AMD, and atrophic AMD developed in the fellow
eye of the remaining subject. The baseline ARM stages of the
second eye were stages 2 (three subjects) and 3 (three sub-
jects).
Progression of Early Stages
Of the 1244 subjects who were included in the early ARM
progression analyses, disease in 316 progressed to a more
severe stage of ARM. For the total cohort, this implied a 2-year
cumulative progression rate of 21.5%. Table 4 shows the inci-
dence rates of the various stages of ARM at follow-up. Age was
associated with progression: Adjusted for gender, follow-up
time, and baseline stage of ARM, the OR of progression for age
per year was 1.04 (95% [CI] 1.01–1.06). Gender was not asso-
ciated with progression: The OR for women versus men was
0.90 (95% CI 0.62–1.31; adjusted for age, follow-up time and
baseline stage of ARM).
In the (univariate) analysis of prognostic factors, macular
area covered by drusen, presence and area of hyperpigmenta-
tion, presence and area of depigmentation, number of small
drusen (,63 mm), and drusen confluence were significantly
associated with progression (data not shown). In the multivar-
iate analysis with the significant factors in the model, all factors
remained statistically significant. A large area of drusen was the
most important predictor of ARM progression: The OR for
more than 10% of macular area covered by drusen was 5.7
(95% CI 2.9–11.3; Table 5). The other important independent
predictors were presence of depigmentation, hyperpigmenta-
tion, 10 or more small drusen, and at least 10% drusen conflu-
ence. Patients with large areas of depigmentation were at a
higher risk of progression than those with smaller areas (OR for
area $175 mm versus area ,175 mm, 2.3; 95% CI 1.5–3.5).
Areas of hyperpigmentation larger than 125 mm did not have
higher ORs than areas of 125 mm or smaller, indicating that
larger areas of hyperpigmentation were not significantly of
additional prognostic value. We found no evidence for statis-
tical interaction between area of drusen and pigmentary irreg-
ularities, between hyper- and depigmentation, or between area
and confluence of drusen (data not shown).
DISCUSSION
In the Rotterdam Study, the incidence rate of AMD was 1.2 per
1000 persons per year for subjects aged 55 years and over. The
incidence rate of AMD showed a strong relation with age and
increased to 8.8 per 1000 persons per year for those aged 85
years and older. The incidence of AMD in the contralateral eye
of subjects already affected by unilateral AMD was 170.6 per
1000 persons per year. The most predictive stage for develop-
ment of incident AMD was ARM stage 3, which comprises the
presence of either soft, indistinct drusen or soft drusen with
pigmentary irregularities. Progression of early stages of ARM
occurred in a very distinct pattern at a rate of 25% in 2 years.
The most important predictors for progression were more than
10% of macular area covered by drusen, presence of depigmen-
tation, and presence of hyperpigmentation.
A good estimate of the incidence of AMD requires the
follow-up of many subjects over a long period, because the
occurrence of this clinical end stage is relatively infrequent. A
large study population with a significant number of elderly is
one of the strengths of the Rotterdam Study. However, the
length of the follow-up period was not long, and the number of
subjects in whom incident AMD developed was low. This
resulted in wide confidence intervals around the estimated
incidence rates. The short follow-up period was a benefit,
however, for the study of the progression of early ARM stages.
FIGURE 1. Comparison of the estimated age-specific incidence rates of
AMD in The Rotterdam Study with the estimated incidence rates in the
Waterman Study,7 and in the Beaver Dam Eye Study.8
TABLE 3. Age-Specific Incidence Rates per 1000 Person-Years, and
2-Year Cumulative Incidences of AMD in the Rotterdam Study
Age
Category
(y)
Person-
Years n
Incidence
Rate 95% CI
2-Year
Cumulative
Incidence
(%)
55–64 3546 0 0 0–1.0 0
65–74 4011 3 0.75 0.15–2.2 0.15
75–84 1952 6 3.07 1.1–6.7 0.61
851 340 3 8.80 1.8–25.8 1.75
Total 9849 12 1.22 0.6–2.1 0.24
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This enabled us to register small changes and to determine a
pattern of progression, which may add to the understanding of
the natural course of this disease.
Loss to follow-up was a concern in this study as it is in all
cohort studies. Nonparticipation in the second round was
mainly due to death and nonresponse to the entire study, not
to the eye examination itself. Comparison of participating and
nonparticipating subjects showed that the latter group was
older and had more vascular disease; however, the groups did
not significantly differ in stage of ARM at baseline. Thus, selec-
tion bias regarding ARM disease status due to loss to follow-up
appears to be limited in our study.
The age-specific incidences of AMD appeared to be lower in
the Rotterdam Study than in the Waterman Study7 and Beaver
Dam Eye Study8 (Fig. 1). The US studies took place in different
parts of the US, but showed incidences within the same range.
Although a longer follow-up period is needed to confirm the
incidences, the difference appears to be considerable, is con-
sistent over the age-groups, and is in agreement with earlier
reports indicating global differences in the occurrence of AMD.
Comparison of prevalence data from the Beaver Dam Eye
Study, the Blue Mountain Eye Study, and the Rotterdam Study
show that the prevalence of AMD is highest in the US and
lowest in The Netherlands.1–3 The three studies used very
similar methods of diagnosis based on fundus photography,
which makes it less likely that the differences were a result of
observation bias. Known risk factors such as smoking and
cardiovascular disease did not explain the differences,13 and it
remains a key point of interest to identify the environmental
and genetic factors that are accountable.
The 2-year cumulative incidence of AMD in the fellow eye
in subjects with unilateral AMD was 29% in the entire study,
and the type of AMD was not necessarily concordant with the
first eye. The Beaver Dam Eye Study found a 5-year incidence
of 22% for the second eye,8 considerably lower than the Rot-
terdam Study. The lower maximum age at baseline in the
Beaver Dam study may account for this difference. Our data are
in line with clinic-based studies reporting the rate of fellow eye
involvement. The majority of these studies focused on patients
with neovascular AMD, and estimates for annual second eye
incidence mostly ranged from 4% to 15%.11,14–19 All preva-
lence figures in these studies were crude prevalences, because
numbers were mostly too small for any stratification. There-
fore, comparison of these prevalences is hampered by differ-
ences in age, duration of disease, and diagnosis. Long-time
follow-up of large, well-defined study groups is needed to
provide valid and precise estimates and to enable more pro-
found comparisons.
An important objective of this study was to describe the
progression of early features of ARM. It has long been known
that soft drusen and pigmentary changes are precursor lesions
that increase the risk of geographic atrophy and neovascular
macular degeneration.7,8,11–21 After appearing, drusen and pig-
mentary changes may regress and disappear, but this may be a
result of appearance of more severe lesions.7,8 In the Rotter-
dam Study, we did not focus on individual fundus lesions. To
enhance clinical relevance, we preferred to study progression
of ARM in exclusive stages of disease. We stratified early fea-
tures of ARM in three stages based on type of drusen and
presence of pigmentary changes, the factors that have been
shown to be strong predictors for the development of
AMD.7,8,11,12 The ranking of the stages proved to be in accor-
dance with clinical severity: the risk of AMD increased from
virtually no risk for stages 0 and 1, to a 2-year risk of 3% and 9%
for stages 2 and 3, respectively. An interesting finding was that
progression was predominantly to only one more advanced
stage at a rate of approximately one-fourth of the cohort per 2
years for the earliest stages (Table 4). Progression from stage 3
to 4 was slower and occurred at a rate of 9% in 2 years. In some
subjects, maculopathy progressed fast and skipped a stage, but
no subjects skipped more than one stage in the 2 years of
follow-up. Although future studies are awaited to confirm these
data, our findings add to the view that development of ARM is
not a random chain of events, but rather seems to follow a
well-defined pattern at a stable rate.
In accordance with Klein et al.,8 we found that a large area
of the macula covered by drusen and pigmentary irregularities
were important predictors of ARM progression, independent
of stage of disease. Other predictors were number of small
drusen and drusen confluence. The number of intermediate
(64–124 mm) and large ($125 mm) drusen did not have addi-
tional predictive power, neither did location of drusen. Al-
though small drusen (#63 mm) are not considered an ARM
feature in the International Classification System, our data in-
dicate that more than 10 small drusen are predictive of ARM
progression, independent of other features. This is consistent
with findings from the Waterman Study7 and the Beaver Dam
Eye Study,8 both of which reported that presence of many
small drusen increases the risk of large and soft indistinct
drusen, but not of AMD.
From our results and those of others we conclude that
progression of early ARM appears to follow a distinct pattern.
A large number of small, hard drusen or isolated pigmentary
changes may indicate the very early start of ARM. Then soft
drusen emerge. Subsequently, at a stable rate, multiple drusen
of various sizes appear and become confluent, the total area
increases, and some of the drusen become soft and indistinct.
TABLE 4. Incidence Rates of Stages of ARM per 1000 Person-Years Based on 2-Year Follow-up
Baseline Stage Person-Years
Stage at Follow-up
1 2 3 4
0 638.99 136.2 (24) 3.1 (1) 0 0
1 936.85 139.8 (24) 10.7 (2) 0
2 498.34 148.5 (26) 14.0 (3)
3 103.74 48.2 (9)
Two-year cumulative incidence, expressed as a percentage, is shown in parentheses.
TABLE 5. Independent Prognostic Fundus Features for
Progression of ARM
Fundus Feature OR (95% CI)*
Total drusen area $10% of grid 5.7 (2.9–11.3)
Presence of depigmentation 4.0 (2.5, 6.4)
Presence of hyperpigmentation 3.4 (2.1, 5.4)
$10 Small drusen (#63 mm) 2.5 (1.5, 4.1)
$10% Drusen confluence 2.5 (1.7, 3.8)
* Based on a model that included these factors and age, baseline
stage of ARM, and duration of follow-up period.
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The appearance of pigmentary changes at this stage, especially
large areas of depigmentation, then further increases the risk of
AMD. Subretinal neovascularization or development of geo-
graphic atrophy denote the end stage of ARM.
In conclusion, the incidence of AMD in the Rotterdam Study
was 1.2 per 1000 subjects per year. Our data provide further
evidence that ARM is a progressive disease with a distinct
temporal sequence of events ultimately resulting in AMD.
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